China News Service, Beijing, October 25 (Li Jingze) China Social Security Association and Social Science Literature Publishing House jointly released the "Medical Security Blue Book: China Medical Security Development Report (2020)" (hereinafter referred to as the "Report") in Beijing on the 25th.
The report pointed out that in the past two years, China's medical security reform has achieved significant initial results in scientific control of fees.
The report pointed out that falsely high drug prices, abuse of medical consumables, large prescriptions, and repeated inspections have always been abnormal phenomena in the medical field. They not only consume huge amounts of medical insurance funds for no reason, directly increase the burden of patients’ medical expenses, but also distort medical services. Acts that undermine the fair and orderly competition in the pharmaceutical market are chronic diseases that must be cured.
According to the report, in the past two years, on the basis of summarizing the previous practical experience in various places, a series of measures have been adopted to adjust the drug catalogue, effectively carry out some drug access negotiations, promote centralized procurement of drugs and medical consumables, and deepen the reform of medical insurance payment methods. Measures have been taken to rectify the above-mentioned problems, and significant initial results have been achieved in scientific control of fees.
To this end, the report lists relevant data to discuss.
For example, in terms of adjusting the drug catalog, the report shows that the National Medical Security Administration of China, in conjunction with the Ministry of Human Resources and Social Security, issued the "Notice on Printing and Distributing the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog" in August 2019. The new version of the medical insurance drug catalog.
Including 2,643 Western medicines and proprietary Chinese medicines, Chinese herbal medicines were changed from the exclusion method to the admission method, and 892 herbal medicines were included in the scope of reimbursement.
On the whole, the goal of significantly optimizing the drug structure and significantly improving drug security capabilities was achieved.
Regarding the negotiation of certain drug access, the report pointed out that on the basis of expert review and calculation and strengthened communication with enterprises, the National Medical Security Administration organized negotiation experts and enterprises to negotiate, and in 2018, 17 anti-cancer drugs were included in the medical insurance catalog. The average price reduction rate reached 56.7%; in 2019, another 70 of 119 medicines were successfully negotiated (including 52 Western medicines and 18 Chinese patent medicines). At the same time, a unified national medical insurance payment standard and limited payment scope were determined and included in the medical insurance catalog For Category B, the average price is reduced by 60% compared to before the negotiation. Most of the successfully negotiated drugs are those newly marketed in recent years and have high clinical value, involving clinical treatment fields such as cancer, rare diseases, hepatitis, rheumatism, and diabetes.
According to the report, as of the end of September 2019, a total of 552,000 people were reimbursed by national medical insurance for 17 anti-cancer drugs, with a reimbursement amount of 3.44 billion yuan, with an average reimbursement ratio of more than 60%, saving patients' personal expenses by 9.39 billion yuan, and significantly reducing the number of insured people Burden of medication. (Finish)